Orcrist Bio Inc. Receives Approval From European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750

September 1st, 2009 BASEL and REINACH, Switzerland - - CAPRA-2-Data Will be Used to File for US Marketing Approval Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM). The CAPRA-2 study (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) was a 12-week, multicentre, double-blind phase III trial evaluating the safety and efficacy of Lodotra(TM) for the treatment of rheumatoid arthritis ("RA"), a chronic, progressive and disabling autoimmune disorder.

July 7th, 2009 CAMBRIDGE, England - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). The Phase I, single ascending dose study was conducted in the United States.

June 28th, 2009 VIENNA - The allocation procedure for the transportation capacities of the Tauern Gas Pipeline project, known as TGL Open Season 2009, starts on 29th June. In this next step of the feasibility study, the market demand will be determined on the basis of binding capacity requests and long-term transportation capacities allocated on a non-discriminatory basis.

June 23rd, 2009 MUMBAI, India - Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFDA - Glenmark takes a step closer towards becoming the first Indian company to have a truly global innovative drug for the world In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight.

June 15th, 2009 BOSTON - Pitavastatin Represents Important Treatment Option for More Vulnerable Populations New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidaemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin. The Phase III data were presented today by Kowa, at the XV International Symposium on Atherosclerosis in Boston.

June 4th, 2009 BERLIN, Germany - Single Dose Palonosetron is Effective and Safe in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Aggressive Non-Hodgkin's Lymphomas who Undergo Moderately Emetogenic Chemotherapy - Data Presented Today at the European Haematology Association Congress in Berlin, Germany New data presented today at the EHA (European Haematology Association) Congress in Berlin show that a single dose of palonosetron, a second generation 5-HT3 receptor antagonist, is effective and safe in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with aggressive non Hodgkin's lymphoma (NHL), treated with cytotoxic agents. The result comes from a study conducted in Italy on behalf of the Italian Group of Study on Lymphomas (GISL) by a multicentric team coordinated by Dr.

May 31st, 2009 CAMBRIDGE, Massachusetts - Results Presented at American Society of Clinical Oncology (ASCO) Meeting Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors - Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana's biodegradable polymer platform, Fleximer(R).

May 5th, 2009 REHOVOT, Israel - D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA.

April 8th, 2009 FLORENCE, Italy - Results Presented at the Annual Congress of the World Psychiatric Association (WPA) ABILIFY(R) (aripiprazole), when used in combination with lithium or valproate, is a generally well-tolerated long-term treatment for patients with Bipolar I Disorder, who are partially non-responsive to lithium or valproate monotherapy.(1) The data presented at the annual congress for the World Psychiatric Association (WPA) report a favourable long-term safety profile for ABILIFY in combination with lithium or valproate.(1) Professor Eduard Vieta, lead study investigator and Professor of Psychiatry and Director of the Bipolar Disorders Programme of the Hospital Clinic at the University of Barcelona, Spain, said "As a doctor, I value data on safety, tolerability and efficacy as extremely important. Clinicians look for treatments that are efficacious and tolerable in the long term.

March 26th, 2009 MUNICH - Edoxaban (DU-176b) is a direct Factor Xa inhibitor and is developed to prevent thromboembolic events such as stroke and pulmonary embolism. The Phase II Edoxaban programme has been successfully completed for orthopaedic and cardiological indications.

September 22nd, 2009 WASHINGTON - For women who experience severe menstrual pain, a new device developed by University of Cincinnati researchers could appear as a blessing. Fed up of the chronic pain, women often end up having medications that can cause gastrointestinal side effects.

May 15th, 2009 WASHINGTON - A five mg dose of Tadalafil (Cialis) daily helped males overcome erectile dysfunction and improved their sexual lives, besides being well tolerated, according to a new study. Erectile dysfunction or ED is consistent inability to attain and maintain an erection sufficient for sexual intercourse.

March 17th, 2009 WASHINGTON - Singer Nelly Furtado has launched her own record label in a bid to lend a helping hand to hopeful musicians. The 'Hey Man' hitmaker has launched her own record label called 'Nelstar' in co-operation with Canadian independent record company Last Gang Labels.

April 13th, 2009 WASHINGTON - Drinking just a cup of black tea regularly may help protect against cardiovascular disease, according to the latest study. The research, conducted by University of L'Aquila in Italy and supported by Lipton Institute of Tea, is the first to show that black tea consumption does improve blood vessel reactivity, and reduce both blood pressure and arterial stiffness, indicating a notably better cardiovascular health profile.

July 3rd, 2009 NEW DELHI - Praising Railways Minister Mamata Banerjee's budget Friday, Prime Minister Manmohan Singh said she had done a "very competent job" and had not just ensured that there was no burden on the passengers but also taken care of their safety. Banerjee had done a "very competent job in a short period of time.

May 18th, 2009 WASHINGTON - Viagra does not pose any apparent long-term threat to men's sight, according to a new study. There were huge concerns that Viagra, and its competitor drug sold in the United States as Cialis, might prove harmful after some men reported blurred and blue-tinged vision.

May 5th, 2009 NEW DELHI - The candidates for the fourth phase of polls Thursday is a mixed bag - 164 have criminal records and 259 are millionaires, a survey said Tuesday. According to the study by the National Election Watch (NEW), '12 percent of the total 1,306 candidates in fray for the fourth phase have criminal records'.

July 10th, 2009 LONDON - An experimental drug called raxibacumab has been found to be effective in treating anthrax poisoning, say researchers. "The results published today showed that a single dose of raxibacumab was highly effective as a treatment for inhalation anthrax in both rabbits and monkeys," said Dr Sally D.

September 1st, 2009 NEW DELHI - Following a spate of accidents at Delhi Metro construction sites, Delhi Government may initiate legal action against Delhi Metro Rail Corporation (DMRC), if it observes fault with pending studies on safety of workers at its sites, said Delhi Labour Secretary K S Wahi on Tuesday. "Definitely we are not satisfied.

July 8th, 2009 NEW DELHI - Union Home Minister P Chidambaram has ruled out any plans to engage private domestic airlines to move paramilitary forces across the country. At present, the Indian Air Force provides air support to paramilitary forces.